Provided by Tiger Fintech (Singapore) Pte. Ltd.

Teva Pharmaceutical

15.90
+0.21001.34%
Post-market: 15.88-0.0200-0.13%19:38 EST
Volume:14.37M
Turnover:228.59M
Market Cap:18.22B
PE:-10.97
High:16.13
Open:15.69
Low:15.68
Close:15.69
Loading ...

BRIEF-Teva Launches Spring Summer 2025 Collection Designed For Playground Earth

Reuters
·
04 Mar

Teva Launches Spring Summer 2025 Collection; Designed for Playground Earth

THOMSON REUTERS
·
04 Mar

Teva to Present at Barclays Global Healthcare Conference and Leerink Partners Global Healthcare Conferences in March

GlobeNewswire
·
04 Mar

Why Axsome Therapeutics, Inc. (AXSM) is Skyrocketing So Far in 2025

Insider Monkey
·
02 Mar

Is Teva Pharmaceuticals Industries Limited (TEVA) the Best Weight Loss Drug Stock to Buy According to Analysts?

Insider Monkey
·
02 Mar

Sanofi's Positive Duvakitug Data Raises Market Questions for Teva Pharmaceutical Industries (NYSE:TEVA)

Simply Wall St.
·
02 Mar

Is Teva Pharmaceutical Industries Limited (TEVA) the Best Low Price Pharma Stock to Invest In Right Now?

Insider Monkey
·
27 Feb

2025 Community Routes: Access to Mental Health Care Grants Awarded to Clinics in Alabama, Mississippi, and Texas, Funded by Teva Pharmaceuticals

THOMSON REUTERS
·
27 Feb

2025 Community Routes: Access to Mental Health Care Grants Awarded to Clinics in Alabama, Mississippi, and Texas, Funded by Teva Pharmaceuticals

GlobeNewswire
·
27 Feb

Teva, Medincell announce FDA acceptance of sNDA for Uzedy

TIPRANKS
·
26 Feb

Teva and Medincell Announce FDA Acceptance of Supplemental New Drug Application for UZEDY(R) (risperidone) Extended-Release Injectable Suspension as a Treatment for Patients with Bipolar I Disorder

GlobeNewswire
·
26 Feb

Teva Pharmaceutical Industries Limited (TEVA): Among Bourgeon Capital’s Top Stock Picks

Insider Monkey
·
26 Feb

Teva Pharmaceutical’s Promising TL1a Program Drives Buy Rating Amid Strong Phase 2 Data for Duvakitug

TIPRANKS
·
25 Feb

Sanofi/Teva Unveil New Detailed Data For Duvakitug Study Supporting Overall Efficacy For Common Inflammatory Bowel Disease

Benzinga
·
24 Feb

Teva, Sanofi present new results from RELIEVE UCCD Phase 2b study

TIPRANKS
·
23 Feb

Exchange-Traded Funds Higher, Equity Futures Mixed Pre-Bell Friday Amid Ongoing Tariff Uncertainties

MT Newswires Live
·
21 Feb